BLACK WEEKSLiekovky −15 % · kity −10 % · ostatné −5 %s kódomDoprava po Nemecku zadarmo od 200 €

Táto stránka bola preložená automaticky a môže obsahovať chyby. Ste rodený hovoriaci? Radi privítame vašu spätnú väzbu a opravy.Poslať spätnú väzbu

The Peptide Desk The Peptide Desk
Tirzepatide, fotografia produktu

8 laboratórnych správ

PDF
99%
Čistota
Testované
Tirzepatide 10mg
Laboratórium
Analiza Białek
Dátum
November 2026
Výsledok
99% purity (10.88 mg measured)
Endotoxíny
5.99 EU/vial
Č. objednávky
Heslo

Testované nezávisle, overiteľné heslom priamo v laboratóriu.

GLP-1

Tirzepatide

GLP-1

Objednávka

Cena za kus - Doprava po Nemecku zadarmo od 200 € počas Black Weeks
  • DHL so sledovaním zásielky
  • Diskrétne balenie

4.6 z 5 na Trustpilote73 hodnotení

Hľadané aj ako: Tirzepatid · Tirze · LY3298176

V skratke

Tirzepatide v číslach

Kľúčové údaje z nášho lexikónu. Posuňte bod po krivke a uvidíte, koľko podľa výpočtu zostáva po jednej dávke.

Celé heslo v lexikóne

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~5 days

Half-life ~5 days
After 10 days: 25 %
Day 550 %Day 7, next dose38 %Day 1025 %Day 1512.5 %Day 253.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

~5days

Class
Dual GIP / GLP-1 agonist
Frequency
Once weeklysubcutaneous
Form
Lyophilised powderreconstituted with BAC water
Sizes
5 to 120 mg10 sizes in the shop

Znalosti

Všetko o Tirzepatide

Podrobné informácie pripravujeme.

Hodí sa priobjednať

Čo k tomu potrebujete

Bakteriostatická voda sa do košíka pridá automaticky. Striekačky a tampóny jedným kliknutím.

Inzulínové striekačky

10 ks · 5.50 €

Alkoholové tampóny

50 ks · 10 €

Koľko vody?

Jednotky na striekačke pre vašu veľkosť liekovky.

Otvoriť kalkulačku →

FAQ

Časté otázky

Zdroje ku každej odpovedi: heslo v lexikóne

Máte ešte otázku?

Napíšte nám, náš tím vám pomôže.

Is Tirzepatide approved?

Yes. The first approval came in May 2022 in the USA for type 2 diabetes, the European Medicines Agency issued a positive opinion shortly after. ChEMBL now lists type 2 diabetes, obesity and overweight as approved indications. The information here describes the state of research and is not a recommendation for use.

How does Tirzepatide differ from Semaglutide and Retatrutide?

The number of receptors. Semaglutide acts only on the GLP-1 receptor, Tirzepatide on GIP and GLP-1, Retatrutide also on the glucagon receptor. In a head-to-head trial against semaglutide (SURMOUNT-5) weight fell by 20.2 versus 13.7 percent after 72 weeks. A comparison with Retatrutide is still running (TRIUMPH-5, planned end November 2026).

What did the phase 3 trials show?

In SURMOUNT-1 (obesity without diabetes) weight fell by 20.9 percent on average after 72 weeks at the highest study dose, by 3.1 percent on placebo. In SURMOUNT-2 (with type 2 diabetes) it was 14.7 versus 3.2 percent. In SURPASS-1 long-term blood sugar (HbA1c) fell by up to 2.07 percentage points in 40 weeks, on placebo it rose slightly.

How long does Tirzepatide stay in the body?

The half-life in the first human study was about five days (116.7 hours on average). A fatty acid attached to the molecule makes this possible: it lets the molecule bind to the blood protein albumin. That fits one dose a week, which is how the trials give it.

What happens after stopping?

SURMOUNT-4 tested this. After 36 weeks of Tirzepatide everyone had lost 20.9 percent on average. Those switched to placebo regained 14.0 percent on average by week 88. Those who continued lost a further 5.5 percent. Over the whole period it was 25.3 versus 9.9 percent.

Which side effects were seen?

Most often gastrointestinal effects such as nausea, diarrhoea and vomiting, mostly mild to moderate and mainly while the dose was being increased. In SURMOUNT-1 4.3 to 7.1 percent stopped because of side effects depending on the dose, 2.6 percent on placebo. A phase 2 trial showed that a lower start and smaller steps went along with fewer complaints.

What is known about heart, liver and sleep apnoea?

In SUMMIT (heart failure with preserved ejection fraction and obesity) 9.9 percent had cardiovascular death or worsening heart failure, 15.3 percent on placebo. In SURPASS-CVOT Tirzepatide was not worse than dulaglutide for cardiovascular events. In SYNERGY-NASH MASH resolved in 62 percent at the highest study dose, in 10 percent on placebo. In sleep apnoea the number of breathing pauses per hour fell by 25.3 in one of the two trials, by 5.3 on placebo.

Which trials are still running?

Six of the listed phase 3 trials are not finished yet. The largest is SURMOUNT-MMO on morbidity and mortality in obesity with 15,374 participants (planned end October 2027). There are also trials in type 1 diabetes, in adolescents and in children aged 6 to 11.

Porovnania

Porovnanie s ostatnými

Súvisiace

Súvisiace produkty